Insmed Incorporated
INSM
Rang in Aktien
#1121
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Aktienkurs
$93.98
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$20.52B
Veränderung (1 Tag)
-1.77%
Veränderung (1 Jahr)
-41.41%
Land
US
Handel Insmed Incorporated (INSM)
Kategorie
Healthcare
Kursverlauf für Insmed Incorporated (INSM)
Höchster Schlusskurs: $100.34 am 2026-10-01
Niedrigster Schlusskurs: $139.94 am 2000-06-01
Niedrigster Schlusskurs: $139.94 am 2000-06-01
Kursverlauf der Aktie von Insmed Incorporated von 2000 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | -25.88% |
| 2025 | 163.90% |
| 2024 | 150.02% |
| 2023 | 48.62% |
| 2022 | -29.22% |
| 2021 | -27.29% |
| 2020 | 59.86% |
| 2019 | 62.30% |
| 2018 | -51.70% |
| 2017 | 128.88% |
| 2016 | -24.86% |
| 2015 | 16.87% |
| 2014 | -8.76% |
| 2013 | 145.55% |
| 2012 | 112.00% |
| 2011 | -49.13% |
| 2010 | -19.73% |
| 2009 | 46.16% |
| 2008 | -42.34% |
| 2007 | -13.04% |
| 2006 | -35.82% |
| 2005 | -15.49% |
| 2004 | -33.15% |
| 2003 | 447.28% |
| 2002 | -85.64% |
| 2001 | 16.21% |
| 2000 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.10 | -4.29% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
